Rhone Poulenc Still Can't Get Any Respect

Rhone-Poulenc chief Jean-Rene Fourtou wishes the market would give his company some credit. Fourtou has made huge strides in turning his $17 billion company into a global player in pharmaceuticals and chemicals. He has sold off commodity businesses and made $11 billion worth of acquisitions in pharmaceuticals, specialty chemicals, and agricultural products. In the latest deal, Rhone-Poulenc Rorer, a big U.S. drugmaker that is two-thirds owned by the French company, bagged British drugmaker Fisons PLC for $2.9 billion. The move boosts Rhone from 14th to 11th place in the global rankings of pharmaceutical companies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.